4.4 Article

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, Research & Experimental

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

Hiroyuki Tanaka et al.

ADVANCES IN THERAPY (2017)

Article Medicine, General & Internal

Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats

Ling Chen et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)

Article Medicine, Research & Experimental

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Hiroaki Iijima et al.

ADVANCES IN THERAPY (2015)

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Endocrinology & Metabolism

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

E. Ferrannini et al.

DIABETES OBESITY & METABOLISM (2013)

Review Urology & Nephrology

Vasopressin: a novel target for the prevention and retardation of kidney disease?

Lise Bankir et al.

NATURE REVIEWS NEPHROLOGY (2013)

Article Endocrinology & Metabolism

Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Jiwen (Jim) Liu et al.

DIABETES (2012)